Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

PaperCitations, authors & open-access status

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 285 citations, 2020 year and bronze oa status.

285
Citations
2020
Year
bronze
OA Status

Related on ScholarIQ

Lin Wang
Author
Jianming Ying
Author
Clinical Cancer Research
Journal
Bladder and Urothelial Cancer Treatments
Topic
Bladder and Urothelial Cancer Treatments
Topic
HER2/EGFR in Cancer Research
Topic
470M+ articles · free account